These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1939 related items for PubMed ID: 16604564

  • 1. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Li CI, Malone KE, Saltzman BS, Daling JR.
    Cancer; 2006 May 15; 106(10):2104-12. PubMed ID: 16604564
    [Abstract] [Full Text] [Related]

  • 2. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.
    Li CI, Daling JR, Malone KE.
    Cancer Epidemiol Biomarkers Prev; 2005 Apr 15; 14(4):1008-11. PubMed ID: 15824180
    [Abstract] [Full Text] [Related]

  • 3. Is there a low-grade precursor pathway in breast cancer?
    King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.
    Ann Surg Oncol; 2012 Apr 15; 19(4):1115-21. PubMed ID: 21935747
    [Abstract] [Full Text] [Related]

  • 4. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL.
    APMIS Suppl; 2003 Apr 15; (108):1-67. PubMed ID: 12874968
    [Abstract] [Full Text] [Related]

  • 5. Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up.
    Ringberg A, Andersson I, Aspegren K, Linell F.
    Eur J Surg Oncol; 1991 Oct 15; 17(5):466-76. PubMed ID: 1657650
    [Abstract] [Full Text] [Related]

  • 6. Epidemiological survey of preinvasive breast cancer.
    Vandenbroucke A, Bourdon C.
    Eur J Cancer Prev; 1993 Nov 15; 2 Suppl 3():3-10. PubMed ID: 8298449
    [Abstract] [Full Text] [Related]

  • 7. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data.
    Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A.
    J Clin Oncol; 2005 Aug 20; 23(24):5534-41. PubMed ID: 16110014
    [Abstract] [Full Text] [Related]

  • 8. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Rudloff U, Brogi E, Brockway JP, Goldberg JI, Cranor M, Wynveen CA, Nehhozina T, Reiner AS, Patil S, Van Zee KJ.
    Cancer; 2009 Mar 15; 115(6):1203-14. PubMed ID: 19170233
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM.
    Cancer; 2006 Jan 01; 106(1):42-50. PubMed ID: 16333852
    [Abstract] [Full Text] [Related]

  • 11. 8. The dilemma of in situ carcinoma of the breast.
    Fentiman IS.
    Int J Clin Pract; 2001 Dec 01; 55(10):680-3. PubMed ID: 11777293
    [Abstract] [Full Text] [Related]

  • 12. Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ.
    Ringberg A, Palmer B, Linell F, Rychterova V, Ljungberg O.
    Eur J Surg Oncol; 1991 Feb 01; 17(1):20-9. PubMed ID: 1847343
    [Abstract] [Full Text] [Related]

  • 13. [Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer].
    Aulmann S, Penzel R, Schirmacher P, Sinn HP.
    Verh Dtsch Ges Pathol; 2007 Feb 01; 91():208-13. PubMed ID: 18314616
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [In situ carcinomas of the breast: clinical features and therapeutic strategies].
    Attene F, Scognamillo F, Trignano E, Meloni GB, Rubino C, Trignano M.
    Ann Ital Chir; 2006 Feb 01; 77(1):3-10; discussion 10-2. PubMed ID: 16910353
    [Abstract] [Full Text] [Related]

  • 16. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
    Fisher ER, Costantino J, Fisher B, Palekar AS, Paik SM, Suarez CM, Wolmark N.
    Cancer; 1996 Oct 01; 78(7):1403-16. PubMed ID: 8839545
    [Abstract] [Full Text] [Related]

  • 17. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.
    Goldstein NS, Kestin LL, Vicini FA.
    Cancer; 2001 Aug 15; 92(4):738-47. PubMed ID: 11550142
    [Abstract] [Full Text] [Related]

  • 18. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation.
    Hill-Kayser CE, Harris EE, Hwang WT, Solin LJ.
    Int J Radiat Oncol Biol Phys; 2006 Dec 01; 66(5):1313-9. PubMed ID: 16997501
    [Abstract] [Full Text] [Related]

  • 19. Lobular neoplasia in breast core needle biopsy specimens is not associated with an increased risk of ductal carcinoma in situ or invasive carcinoma.
    Renshaw AA, Cartagena N, Derhagopian RP, Gould EW.
    Am J Clin Pathol; 2002 May 01; 117(5):797-9. PubMed ID: 12090431
    [Abstract] [Full Text] [Related]

  • 20. Patterns of treatment for ductal carcinoma in situ of the breast in Louisiana, 1988-1999.
    Wu X, Chen VW, Ruiz B, Andrews PA, Hsieh MC, Schmidt BA, Correa CN, Fontham ET.
    J La State Med Soc; 2003 May 01; 155(4):206-13. PubMed ID: 14506828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 97.